免疫微环境在肺癌中的研究进展

Abstract
Figure/Table
References (35)
Related Citation (15)

Download: PDF (560 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract The tumor microenvironment plays a central role in the initiation and progression of lung cancer. The innate and adaptive immune cells in tumor microenvironment have the effect of promoting and suppressing tumor. Tumor cells escaped from the surveillance and killing of immune cells by over-expressing immune checkpoint molecules, resulting in the acceleration of tumor growth. Currently, immune checkpoint inhibitors for advanced non-small cell lung cancer have been written in various clinical practice guidelines. Immunotherapy is aimed at improving immune cell function or inhibiting the activity of immune checkpoints. Therefore, further understanding of the immunomodulatory function of the immune cells may help to improve the efficacy of immunotherapy and discover new therapeutic targets.

Key words： Tumor microenvironment Lung cancer Immune cells Immunotherapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Liang PENG Min WENG Yiming SONG Qibin

Cite this article:

CHEN Liang PENG Min WENG Yiming SONG Qibin. Research progress on immune microenvironment of lung cancer[J]. 中国医药导报, 2019, 16(35): 28-30,43.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I35/28

[1] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
[2] Siegel RL，Miller KD，Jemal A. Cancer statistics，2018 [J]. CA Cancer J Clin，2018，68（1）：7-30.
[3] Herbst RS，Morgensztern D，Boshoff C. The biology and management of non-small cell lung cancer [J]. Nature，2018， 553（7689）：446-454.
[4] Chen Z，Fillmore CM，Hammerman PS，et al. Non-small-cell lung cancers：a heterogeneous set of diseases [J]. Nat Rev Cancer，2014，14（8）：535-546.
[5] Mayekar MK，Bivona TG. Current Landscape of Targeted Therapy in Lung Cancer [J]. Clin Pharmacol Ther，2017， 102（5）：757-764.
[6] Dougan M，Dougan SK. Targeting Immunotherapy to the Tumor Microenvironment [J]. J Cell Biochem，2017，118（10）：3049-3054.
[7] Engblom C，Pfirschke C，Pittet MJ. The role of myeloid cells in cancer therapies [J]. Nat Rev Cancer，2016，16（7）：447-462.
[8] Lavin Y，Kobayashi S，Leader A，et al. Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses [J]. Cell，2017，169（4）：750-765.e17.
[9] Choi H，Sheng J，Gao D，et al. Transcriptome analysis of individual stromal cell populations identifies stroma-tumor crosstalk in mouse lung cancer model [J]. Cell Rep，2015， 10（7）：1187-1201.
[10] Kastenmüller W，Kastenmüller K，Kurts C，et al. Dendritic cell-targeted vaccines--hope or hype？[J]. Nat Rev Immunol，2014，14（10）：705-711.
[11] Janakiram M，Shah UA，Liu W，et al. The third group of the B7-CD28 immune checkpoint family：HHLA2，TMIGD2，B7x，and B7-H3 [J]. Immunol Rev，2017，276（1）：26-39.
[12] Mohan T，Zhu W，Wang Y，et al. Applications of chemokines as adjuvants for vaccine immunotherapy [J]. Immunobiology，2018，223（6/7）：477-485.
[13] Lee JM，Lee MH，Garon E，et al. Phase Ⅰ Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration [J]. Clin Cancer Res，2017，23（16）：4556-4568.
[14] Veglia F，Perego M，Gabrilovich D. Myeloid-derived suppressor cells coming of age [J]. Nat Immunol，2018，19（2）：108-119.
[15] Coffelt SB，Wellenstein MD，de Visser KE. Neutrophils in cancer：neutral no more [J]. Nat Rev Cancer，2016，16（7）：431-446.
[16] Condamine T，Dominguez GA，Youn JI，et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients [J]. Sci Immunol，2016，1（2）：pii：aaf8943.
[17] Almatroodi SA，McDonald CF，Darby IA，et al. Characterization of M1/M2 Tumour-Associated Macrophages (TAMs) and Th1/Th2 Cytokine Profiles in Patients with NSCLC [J]. Cancer Microenviron，2016，9（1）：1-11.
[18] Kumar V，Donthireddy L，Marvel D，et al. Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors [J]. Cancer Cell，2017，32（5）：654-668. e5.
[19] Conway EM，Pikor LA，Kung SH，et al. Macrophages，Inflammation，and Lung Cancer [J]. Am J Respir Crit Care Med，2016，193（2）：116-130.
[20] Sionov RV，Fridlender ZG，Granot Z. The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment [J]. Cancer Microenviron，2015，8（3）：125-158.
[21] McLoed AG，Sherrill TP，Cheng DS，et al. Neutrophil-Derived IL-1β Impairs the Efficacy of NF-κB Inhibitors against Lung Cancer [J]. Cell Rep，2016，16（1）：120-132.
[22] Bauer AK，Velmurugan K，Xiong KN，et al. Epiregulin is required for lung tumor promotion in a murine two-stage carcinogenesis model [J]. Mol Carcinog，2017，56（1）：94-105.
[23] Engblom C，Pfirschke C，Zilionis R，et al. Osteoblasts remotely supply lung tumors with cancer-promoting Siglec-Fhigh neutrophils [J]. Science，2017，358（6367）：pii：eaal5081.
[24] Cerwenka A，Lanier LL. Natural killers join the fight against cancer [J]. Science，2018，359（6383）：1460-1461.
[25] Picard E，Godet Y，Laheurte C，et al. Circulating NKp46+Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer [J]. Oncoimmunology，2018，8（2）：e1527498.
[26] Carrega P，Ferlazzo G. Natural Killers Are Made Not Born：How to Exploit NK Cells in Lung Malignancies [J]. Front Immunol，2017，8：277.
[27] Bj?觟rkstr?觟m NK，Ljunggren HG，Micha?觕lsson J. Emerging insights into natural killer cells in human peripheral tissues [J]. Nat Rev Immunol，2016，16（5）：310-320.
[28] Reiser J，Banerjee A. Effector，Memory，and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response [J]. J Immunol Res，2016，2016：8941260.
[29] Ganesan AP，Johansson M，Ruffell B，et al. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma [J]. J Immunol，2013，191（4）：2009-2017.
[30] Wherry EJ，Kurachi M. Molecular and cellular insights into T cell exhaustion [J]. Nat Rev Immunol，2015，15（8）：486-499.
[31] Boussiotis VA. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway [J]. N Engl J Med，2016，375（18）：1767-1778.
[32] Markowitz GJ，Havel LS，Crowley MJ，et al. Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival [J]. JCI Insight，2018，3（13）.pii：96836.
[33] Marshall EA，Ng KW，Kung SH，et al. Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis [J]. Mol Cancer，2016，15（1）：67.
[34] Germain C，Gnjatic S，Tamzalit F，et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer [J]. Am J Respir Crit Care Med，2014，189（7）：832-844.
[35] Bruno TC，Ebner PJ，Moore BL，et al. Antigen-Presenting Intratumoral B Cells Affect CD4+TIL Phenotypes in Non-Small Cell Lung Cancer Patients [J]. Cancer Immunol Res，2017，5（10）：898-907.